Ramaswami U, Futema M, Bogsrud MP, et al. - Researchers analyzed data from 3,064 children with heterozygous familial hypercholesterolaemia (HeFH) recruited from Norway, UK, Netherlands, Belgium, Czech Republic, Austria, Portugal and Greece, to compare the characteristics as well as lipid levels among these children, given consideration of statin therapy by age 8–10 years for HeFH children with a low density lipoprotein cholesterol (LDL-C) > 3.5 mmol/l, and dietary and lifestyle advice, has been recommended by European guidelines. Across 8 countries, significant differences were evident for the age of HeFH diagnosis in children as well as for the proportion of those > 10 years being managed with statin and/or ezetimibe. They found LDL-C levels over 3.5 mmol/l in nearly a quarter of the treated children and approximately three quarters of the untreated children older than 10 years. The non-receipt of the full potential advantage of early detection and suitable lipid-lowering treatment as per recommendations was noted in many children with FH.